| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.31% | 98.41% | 98.84% | 97.60% | 98.66% | 98.36% | 99.61% | 99.70% | 101.28% | 107.55% | — | — |
| Operating Margin | -40.45% | -67.37% | -44.91% | -69.84% | -3.72% | -23.60% | 32.59% | -10.23% | 4.83% | -13.36% | -26.70% | -22.29% |
| EBITDA Margin | -39.38% | -66.01% | -43.60% | -67.40% | -1.81% | -21.76% | 33.71% | -8.45% | 6.15% | -11.20% | -24.24% | -19.31% |
| Net Margin | -40.41% | -64.37% | -46.50% | -45.92% | -3.53% | -61.88% | 26.20% | 45.65% | -1.18% | -24.97% | -31.12% | -18.20% |
| Current Ratio | 3.83 | 8.47 | 5.90 | 7.07 | 9.75 | 3.65 | 9.97 | 7.88 | 5.20 | 5.96 | 5.62 | 7.25 |
| Quick Ratio | 3.81 | 8.43 | 5.83 | 7.00 | 9.65 | 3.62 | 9.90 | 7.85 | 5.15 | 5.96 | 5.62 | 7.25 |
| Debt / Equity | 3.60 | 2.04 | 3.21 | 2.05 | — | — | — | — | — | — | — | — |
| ROE | -77.98% | -77.15% | -94.72% | -47.08% | -3.71% | -53.51% | 17.46% | 23.06% | -1.43% | -86.93% | -43.97% | -15.12% |
| ROA | -10.82% | -15.11% | -12.25% | -10.64% | -1.09% | -18.88% | 9.10% | 10.26% | -0.45% | -9.49% | -9.23% | -4.08% |
| Asset Turnover | 0.27 | 0.23 | 0.26 | 0.23 | 0.31 | 0.31 | 0.35 | 0.22 | 0.38 | 0.38 | 0.30 | 0.22 |
| Book Value / Share | 3.06 | 3.94 | 2.70 | 4.04 | 5.47 | 6.04 | 11.79 | 8.86 | 3.32 | 0.82 | 1.68 | 2.19 |
Ionis Pharmaceuticals, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of human therapeutics using antisense technology. This proprietary platform enables the creation of novel drugs targeting difficult-to-treat diseases across cardiovascular, metabolic, neurological, and rare disease areas. Key marketed products include TRYNGOLZA (olezarsen), the first FDA-approved treatment for adults with familial chylomicronemia syndrome as an adjunct to diet; DAWNZERA (donidalorsen), an RNA-targeted prophylactic therapy for hereditary angioedema in patients 12 years and older; and royalties from partnered drugs such as SPINRAZA (nusinersen) for spinal muscular atrophy, WAINUA (eplontersen) for polyneuropathy of hereditary transthyretin-mediated amyloidosis, Qalsody for ALS, Tegsedi, and Waylivra. Ionis maintains a broad pipeline of investigational medicines, including olezarsen for severely elevated triglycerides, zilganersen for Alexander disease, bepirovirsen for chronic hepatitis B, ulefnersen for FUS-ALS, sapablursen for polycythemia vera, and opemalirsen for APOL1-mediated kidney disease. The company generates revenues from product sales, royalties, and R&D collaborations with partners like Biogen and AstraZeneca. Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals plays a pivotal role in advancing RNA-targeted therapies for unmet medical needs.